Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing use of opioids
3.2.1.2 Rising prevalence of gastrointestinal disorders
3.2.1.3 Surging expenditure on the R&D of novel treatments
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of awareness regarding adverse effects of opioids
3.3 Growth potential analysis
3.4 Porter's analysis
3.4.1 Supplier power
3.4.2 Buyer power
3.4.3 Threat of new entrants
3.4.4 Threat of substitutes
3.4.5 Industry rivalry
3.5 PESTEL analysis
3.6 Pricing analysis, 2023
3.7 Reimburesemnt scenario
3.8 Regulatory landscape
3.9 Technological landscape
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Peripherally acting mu-opioid receptor agonists (PAMORAs)
5.3 Chloride channel-2 activators
5.4 Laxatives
5.5 Proton pump inhibitors
5.6 Anti-diarrheal
5.7 Other drug classes
Chapter 6 Market Estimates and Forecast, By Prescription Type, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Prescribed drugs
6.3 Over-the-counter (OTC) drugs
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Injectable
Chapter 8 Market Estimates and Forecast, By By Distribution Channel, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Atlantis Consumer Healthcare Inc.
10.2 Bausch Health Companies Inc.
10.3 Bayer AG
10.4 Cumberland Pharmaceuticals Inc.
10.5 Mallinckrodt Pharmaceuticals
10.6 Sanofi
10.7 Shionogi & Co., Ltd.
10.8 Valinor Pharma, LLC
